| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
57,120 |
46,570 |
$715K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
16,007 |
12,932 |
$302K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
8,018 |
7,571 |
$155K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
1,472 |
802 |
$38K |
| 64483 |
|
544 |
424 |
$37K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,866 |
2,761 |
$35K |
| 80305 |
|
11,435 |
9,781 |
$31K |
| 62369 |
|
740 |
592 |
$13K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
852 |
664 |
$12K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
216 |
187 |
$12K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
368 |
312 |
$11K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,081 |
938 |
$11K |
| 27096 |
|
137 |
109 |
$9K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
125 |
110 |
$8K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
378 |
344 |
$8K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
3,052 |
2,245 |
$6K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
505 |
453 |
$6K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
183 |
152 |
$6K |
| 76942 |
|
402 |
350 |
$5K |
| 99152 |
|
513 |
357 |
$5K |
| 99177 |
|
821 |
595 |
$4K |
| L0637 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
17 |
14 |
$4K |
| 62370 |
|
189 |
137 |
$4K |
| 92552 |
|
197 |
159 |
$3K |
| 99215 |
Prolong outpt/office vis |
94 |
82 |
$3K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
25 |
24 |
$2K |
| 64493 |
|
90 |
59 |
$2K |
| 99383 |
|
22 |
15 |
$2K |
| 90686 |
|
381 |
302 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
492 |
390 |
$885.27 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
91 |
80 |
$877.72 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
58 |
56 |
$839.14 |
| 87428 |
|
14 |
12 |
$826.67 |
| 96127 |
|
216 |
172 |
$820.33 |
| 64494 |
|
88 |
58 |
$759.11 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
60 |
52 |
$712.86 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
58 |
27 |
$394.20 |
| 96160 |
|
170 |
108 |
$359.95 |
| 90461 |
|
175 |
132 |
$258.84 |
| 90670 |
|
50 |
43 |
$258.51 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
694 |
523 |
$141.02 |
| 95991 |
|
13 |
12 |
$128.37 |
| 90698 |
|
19 |
15 |
$123.66 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
12 |
12 |
$107.67 |
| 90680 |
|
17 |
13 |
$105.31 |
| 99442 |
|
16 |
16 |
$104.83 |
| 20611 |
|
16 |
14 |
$93.60 |
| 96161 |
|
31 |
28 |
$91.19 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
715 |
515 |
$33.30 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
226 |
154 |
$33.10 |
| 64495 |
|
14 |
13 |
$8.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
56 |
35 |
$4.28 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
62 |
39 |
$0.24 |
| 3008F |
|
144 |
106 |
$0.00 |